[New kinds of AIDS drugs inhibit HIV entry into the cell. Entry inhibitors soon for oral administration].
Entry inhibitors include a variety of drugs with different points of attack and with the common objective of preventing the entry of HIV into the cell. Whereas the only previously approved medication from this group, enfuvirtide, can be only injected subcutaneously and, thus, is indicated for only treatment-experienced patients, the CCR5 antagonists represent a group of experimental medications whose use is conceivable at all stages of the HIV infection. According to the available data, they are effective and also very well tolerated and, therefore, are one of the most promising future classes of drugs. At the moment, the prospective importance of substances possessing other mechanisms of action (attachment inhibitors, CXCR4 inhibitors) can not yet be predicted.
Fätkenheuer
G
G
Klinik I für Innere Medizin--Infektio- logie, Universitäts-klinikum Köln. g.faetkenheuer@uni-koeln.de
D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D024882:Drug Resistance, Viral; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D054398:Receptors, CCR4; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*; D011991:Receptors, Virus / Q000037:antagonists & inhibitors*; D019233:Retreatment; D038301:Virus Inactivation / Q000187:drug effects; D016662:Virus Integration / Q000187:drug effects*
D019380:Anti-HIV Agents; C515354:CCR4 protein, human; D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors; D054398:Receptors, CCR4; D019707:Receptors, Chemokine; D011991:Receptors, Virus